Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 6 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 2 |
| Stem Cell Research Market to 2017 - Introduction | 10 | 2 |
| GBI Research Report Guidance | 11 | 1 |
| Stem Cell Research Market to 2017- Market Overview | 12 | 8 |
| Stem Cell Research An Introduction | 12 | 1 |
| Types of Stem Cell Research | 12 | 2 |
| Current Utilization of Different Types of Stem Cells | 14 | 1 |
| Unmet Needs | 14 | 4 |
| Applications of Stem Cell Research | 18 | 2 |
| Stem Cell Research Market to 2017- Market Characterization | 20 | 25 |
| Stem Cell Market An Introduction | 20 | 1 |
| Market Sizing | 21 | 3 |
| Therapy Cost | 24 | 1 |
| Technology Adoption Framework | 25 | 1 |
| Types of Business Models | 26 | 1 |
| Market Drivers | 27 | 1 |
| Immense Market Opportunity for Stem Cell Research for Certain Disorders with High Unmet Need in Terms of Safe and Efficacious Drugs | 27 | 1 |
| Encouraging Political Environment on Embryonic Stem Cell Research in the US | 28 | 1 |
| Advances in Induced Pluripotent Stem Cells (iPSC) can Decrease Dependency on Embryonic Stem Cells and Increase the Acceptance of Stem Cell Therapy | 29 | 1 |
| Market Barriers &Challenges | 30 | 1 |
| High Cost of Research Demands High Investments in the Stem Cell Research and Development | 30 | 1 |
| Uncertain Reimbursement Scenario for Stem Cell Therapies Due to High Treatment Cost and Unclear Cost-Benefit Ratio | 31 | 1 |
| Ethical, Legal and Social Issues Continue to Remain a Challenge Albeit with Reduced Impact | 32 | 1 |
| Management of Best Scientific Talent for Stem Cell Research Based Companies Remains a Key Area of Focus to Sustain High Quality Research | 33 | 1 |
| Stem Cell Research and Development - Market Trends | 34 | 1 |
| Booming Stem Cell Tourism is a Potential Opportunity for Countries to Attract Investments | 34 | 1 |
| ASLAP Analysis of Stem Cell Tourism | 35 | 1 |
| The Present Situation | 35 | 1 |
| Actors | 36 | 1 |
| Process | 36 | 1 |
| Learning | 36 | 1 |
| Actions | 36 | 1 |
| Performance | 36 | 1 |
| Federal Funding Support Improves the Stem Cell Research Environment | 37 | 1 |
| Increasing Entry of Pharmaceutical Companies Boosts Stem Cell Research &Development | 38 | 1 |
| PESTLE Analysis of Stem Cell Research | 39 | 1 |
| Political Environment | 40 | 1 |
| Economic Environment | 40 | 1 |
| Society | 40 | 1 |
| Technology | 40 | 1 |
| Legislation | 40 | 1 |
| Environment | 40 | 1 |
| SWOT Analysis of Stem Cell Research &Development | 41 | 1 |
| Strengths | 41 | 1 |
| Weakness | 41 | 1 |
| Opportunities | 41 | 1 |
| Threats | 42 | 1 |
| Market Analysis | 43 | 1 |
| Industry Rivalry | 44 | 1 |
| Threat of New Entrant | 44 | 1 |
| Threat of Substitutes | 44 | 1 |
| Supplier Power | 44 | 1 |
| Buyer Power | 44 | 1 |
| Stem Cell Research Market to 2017 - Pipeline Analysis | 45 | 36 |
| Discovery | 45 | 1 |
| IND Filed | 46 | 1 |
| Pre-Clinical | 46 | 3 |
| Phase I | 49 | 5 |
| Phase II | 54 | 22 |
| Phase III | 76 | 5 |
| Stem Cell Research Market to 2017 - Investment Trends | 81 | 32 |
| Investor s Perspective on Stem Cell Research | 81 | 1 |
| Status of Research | 82 | 1 |
| Regulatory Position | 82 | 1 |
| Clinical Development | 82 | 1 |
| Commercial Models | 82 | 1 |
| Patent Policy | 83 | 1 |
| NIH Spending in Stem Cell Research and Development is Increasing and is Supportive | 83 | 1 |
| NIH Spending by Therapeutic Areas | 84 | 17 |
| Segmentation of Funding Received by Therapeutic Areas | 101 | 1 |
| Segmentation of Funding Received by Therapeutic Areas in 2009 | 102 | 1 |
| Segmentation of Funding Received by Therapeutic Areas in 2010 | 103 | 1 |
| Segmentation of Funding Mechanisms by Value in 2009 | 104 | 2 |
| Segmentation of Funding Mechanisms by Value in 2010 | 106 | 1 |
| Segmentation by Total Value of Therapeutic Areas in 2009 | 107 | 1 |
| Segmentation by Total Value of Therapeutic Areas in 2010 | 108 | 1 |
| Segmentation by Total Value of the Funding Mechanisms in 2009 and 2010 | 109 | 1 |
| High Budget Projects Funded by NIH | 110 | 1 |
| BBSRC Funding in Stem Cell Research | 111 | 2 |
| Stem Cell Research Market to 2017 - Geographical Trends | 113 | 18 |
| Stem Cell Companies by Geographic Regions | 113 | 2 |
| The US | 115 | 1 |
| The UK | 116 | 1 |
| China | 117 | 1 |
| Netherlands | 118 | 1 |
| Singapore | 119 | 1 |
| South Korea | 120 | 1 |
| Japan | 121 | 1 |
| India | 122 | 1 |
| Sweden | 123 | 1 |
| Denmark | 124 | 1 |
| France | 125 | 1 |
| Germany | 126 | 1 |
| Israel | 127 | 1 |
| Australia | 128 | 1 |
| Canada | 129 | 1 |
| Czech Republic | 130 | 1 |
| Stem Cell Research Market to 2017 - Mergers and Acquisitions | 131 | 9 |
| Mergers and Acquisitions | 131 | 1 |
| Overview | 131 | 1 |
| Segmentation by Type | 132 | 1 |
| Segmentation of Deal Value | 132 | 1 |
| Segmentation of Deal Number | 133 | 1 |
| Segmentation by Region | 134 | 1 |
| Segmentation of Deal Value | 134 | 1 |
| Segmentation of Deal Number | 135 | 1 |
| Licensing Agreements and Co-Development | 136 | 1 |
| Segmentation by Region | 136 | 1 |
| Segmentation of Deal Value | 136 | 1 |
| Segmentation of Deal Number | 137 | 1 |
| Segmentation by Deal Type | 138 | 1 |
| Segmentation of Deal Value | 138 | 1 |
| Segmentation of Deals Number | 139 | 1 |
| Stem Cell Research Market to 2017 - Company Profiles | 140 | 14 |
| Aastrom Biosciences | 140 | 1 |
| Athersys Inc. | 141 | 1 |
| Osiris Therapeutics | 142 | 1 |
| Bioheart | 143 | 1 |
| Aldagen | 144 | 1 |
| Mesoblast | 145 | 1 |
| Geron | 146 | 1 |
| Advanced Cell Technology | 147 | 1 |
| Cytori Therapeutics | 148 | 1 |
| Pluristem Therapeutics | 149 | 1 |
| Medistem | 150 | 1 |
| NeoStem | 151 | 1 |
| Helix Therapeutics | 152 | 1 |
| StemCells Inc. | 153 | 1 |
| Stem Cell Research Market to 2017- University Profiles | 154 | 2 |
| University of California, San Francisco | 154 | 1 |
| University of Washington | 155 | 1 |
| Stem Cell Research Market to 2017 - Conclusion | 156 | 1 |
| Stem Cell Research Market to 2017- Appendix | 157 | 4 |
| Market Definitions | 157 | 1 |
| Abbreviations | 157 | 1 |
| Methodology | 157 | 4 |
| Coverage | 157 | 1 |
| Secondary Research | 158 | 1 |
| Primary Research | 158 | 1 |
| Market Characterization | 159 | 1 |
| Investment Trends | 159 | 1 |
| Pipeline Analysis | 159 | 1 |
| Mergers and Acquisitions | 159 | 1 |
| Geographical Trends | 159 | 1 |
| Company Profiles | 159 | 1 |
| Expert Panels | 160 | 1 |
| Contact Us | 160 | 1 |
| Disclaimer | 160 | 1 |
| Sources | 160 | 1 |